GLPG - Gilead's Revenues Stabilize Supporting Its Outlook
By Callum Turcan
Data by YCharts
Image Shown: Shares of Gilead Sciences Inc. (GILD) have come under immense pressure since mid-2015, however, with the company's revenues now stabilizing Gilead's outlook is getting brighter.
Gilead Sciences Inc. recently delivered some good news as the firm announced that it was working with global authorities to advance an experimental drug (remdesivir) to treat the novel coronavirus (‘2019-nCoV’) outbreak centered in China. That treatment has been shown to potentially have a chance of treating Ebola (limited emergency field testing), MERS, and SARS, and please note MERS and